Canada markets closed

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.31+0.37 (+1.43%)
At close: 4:00PM EST
Sign in to post a message.
  • H
    Hugh
    Why would a drug that causes mutations be acceptable for a disease like myelofibrosis where patients are already at risk for developing leukemia -- is enhancing that risk OK? Sounds like a Black Box warning on the label at a minimum.
  • V
    V.
    why is this down today?
  • R
    Rocket blaster 2.0
    To the moon?
  • s
    stiglg6
    I think the disease modifying activity indicated by the manifest trial hints that a combination therapy with imetelstat would be beneficial.
  • C
    Chris
    After today's news Oppenheimer raised their target price on CNST to $40 from $18 - maintaining an outperform rating
  • d
    dave
    $21 Price Target by Oppenheimer. Today $8.75 REBOUND? Oppenheimer Thinks Constellation Pharmaceuticals Inc’s Stock is Going to Recover
    In a report released Dec 11, 2018, Leah R. Cann from Oppenheimer initiated coverage with a Buy rating on Constellation Pharmaceuticals Inc (CNST) and a price target of $21.
  • s
    stiglg6
    . CNSTs BET inhibitor, slows down growth, and somehow activates caspases downstream to kill the cell. this is the same thing that geron's imetelstat does. onyl difference being that telomerase is upregulated in 90% of all cancer cell lines while BET is only upregulated in some.

    only the preliminary results have been reported by CNST
    the BETi only works in some cancer cell lines so they decided not to risk it and go straight to combos.
    on the other hand, imetelstat, capable of working on 90% of cancer cell lines as usually lended to single agent trials to demonstrate baseline efficacy and safety.
    we have good reason to believe imetelstat would work in combo with jakafi and CNST's BETi.

    Right now imetelstat has demonstrated a 21 month surivival advantage in the r/r MF cohort that was expected to live 12 months.

    the frontline treatment (jakafi) only yielded an 18 month survival advantage of patients that were expected to live 3.6 years.

    imetelstat is 3 times better than the frontline and there is a preclinical showing it would work well in combo with the frontline. all this hype over CNST's preliminary data is undeserved.
  • H
    Hugh
    why would anybody buy now? There's no news for years. Why even own it now? They can't accelerate with more cash.
  • s
    s p
    got a few shares not going in too deep right off the bat. Most of these newly listed drop like a rock.
  • R
    Richard
    love to know offering price
  • B
    Ballsio
    this is funny, investors taken to the wood shed as it was $20 dollars higher this morning. selling the profits for year end tax management maybe? Bring those profits over to GERN gullable ones.
  • C
    Christian
    Anyone know if there is a discord group for discussion about CNST?
  • b
    biotexx
    $GERN conversation
    @noBALLSio $CNST the plunge seemed to be a short term buying opportunity. Climbed back up to $40. Just 3 months ago we were around $6... but yes...it feels like high risk this could be imploding any time. Just like here at $GERN... 😂😂😂
  • L
    Lorax
    missed the boat on this one... congrats to all longs!
  • B
    Ballsio
    man, that is like $650M market cap. lost in 5 hours. Ouchey.
  • J
    Joseph
    Oppenheimer investor conference today.anyone listen ?
  • F
    F0RD1
    Would anyone on this board know the history/timeline on CPI-1205? My father in law just went on it last week to help battle his prostate cancer. It sounds like he is one of a few in the trials for prostate and I'm trying to find more information. He has a checkup on Monday so hopefully the initial news is good. Thank you for any feedback.
  • T
    Truthseeking
    I expect to see $35 by EOD and possible $40 after hour.
    This kind of news usually produces a triple in biotech stocks price.
  • Y
    Yahoo Finance Insights
    Constellation is up 12.49% to 36.20
  • i
    iceknight
    For those that are curious about the offering price, check out the prospectus at sec website (sec.gov ) and go to the section listed as 'dilution' in there.

    See direct link to sec if yahoo allows it.

    Otherwise it looks like 35.05 is some type of estimated common stock value at offering.
    424B5
    www.sec.gov